ArticleArchives of internal medicine2009
Risk factors for fluconazole-resistant Candida glabrata bloodstream infections.
Article in Archives of internal medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 82 citations in OpenAlex.
- Thermoresponsive carbohydrate polymer mucoadhesive gel for synergistic delivery of acarbose and fluconazole against Candida biofilms.Scientific reports · 2026Article
- Evaluating the Prognostic Value of the EQUAL Candida Score and a Nomogram-Based Approach for Candidaemia-Related Mortality.Mycoses · 2025Article
- Article
- Antifungal Susceptibility Pattern ofJournal of fungi (Basel, Switzerland) · 2023Article
- Comparative Efficacy of Antifungal Agents Used in the Treatment of Oropharyngeal Candidiasis among HIV-Infected Adults: A Systematic Review and Network Meta-Analysis.Journal of fungi (Basel, Switzerland) · 2021Review
- Reducing Duration of Antibiotic Use for Presumed Neonatal Early-Onset Sepsis in Greek NICUs. A "Low-Hanging Fruit" Approach.Antibiotics (Basel, Switzerland) · 2021Article
- Analysis of fungal bloodstream infection in intensive care units in the Meizhou region of China: species distribution and resistance and the risk factors for patient mortality.BMC infectious diseases · 2020Article
- Creation and assessment of a clinical predictive model for candidaemia in patients with candiduria.Mycoses · 2019Article
- Effect of Perillaldehyde on Prophylaxis and Treatment of Vaginal Candidiasis in a Murine Model.Frontiers in microbiology · 2019Article
- Clonal Spread of Candida glabrata Bloodstream Isolates and Fluconazole Resistance Affected by Prolonged Exposure: a 12-Year Single-Center Study in Belgium.Antimicrobial agents and chemotherapy · 2018Article
- Identification and antifungal susceptibility of Candida species isolated from the urine of patients in a university hospital in Brazil.Revista do Instituto de Medicina Tropical de Sao Paulo · 2017Article
- Cross-resistance between voriconazole and fluconazole for non-albicans Candida infection: a case-case-control study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2017Article
- Azole Resistance in Candida glabrata.Current infectious disease reports · 2016Review
- Occurrence of oral Candida colonization and its risk factors among patients with malignancies in China.Clinical oral investigations · 2016Observational
- Azole Antifungal Resistance inFrontiers in microbiology · 2016Review
- A Prospective Surveillance Study of Candidaemia: Epidemiology, Risk Factors, Antifungal Treatment and Outcome in Hospitalized Patients.Frontiers in microbiology · 2016Article
- Article
- Screening of Pharmacologically Active Small Molecule Compounds Identifies Antifungal Agents Against Candida Biofilms.Frontiers in microbiology · 2015Article
- The epidemiology, antifungal use and risk factors of death in elderly patients with candidemia: a multicentre retrospective study.BMC infectious diseases · 2014Article
- The Candida pathogenic species complex.Cold Spring Harbor perspectives in medicine · 2014Review
Corrections and comments
- Commented on by
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundBloodstream infections (BSIs) caused by Candida glabrata have increased substantially. Candida glabrata is often associated with resistance to fluconazole therapy. However, to our knowledge, risk factors for fluconazole-resistant C glabrata BSIs have not been studied.
methodsA case-case-control study was conducted at 3 hospitals from January 1, 2003, to May 31, 2007. The 2 case groups included patients with fluconazole-resistant C glabrata BSIs (minimum inhibitory concentration > or =16 microg/mL) and patients with fluconazole-susceptible C glabrata BSIs (minimum inhibitory concentration < or =8 microg/mL). Hospitalized patients without C glabrata BSIs were randomly selected for inclusion in the control group and were frequency matched to cases on the basis of time at risk. Two case-control studies were performed using this shared control group. The primary risk factor of interest, previous fluconazole use, was evaluated at multivariate analyses, adjusting for demographic data, comorbid conditions, and antimicrobial exposures.
resultsWe included 76 patients with fluconazole-resistant C glabrata BSIs, 68 patients with fluconazole-susceptible C glabrata BSIs, and 512 control patients. Previous fluconazole use (adjusted odds ratio [95% confidence interval], 2.3 [1.3-4.2]) and linezolid use (4.6 [2.2-9.3]) were independent risk factors for fluconazole-resistant C glabrata BSIs; previous cefepime use (2.2 [1.2-3.9]) and metronidazole use (2.0 [1.1-3.5]) were independent risk factors for fluconazole-susceptible C glabrata BSIs.
conclusionsPrevious fluconazole use is a significant risk factor for health care-associated fluconazole-resistant C glabrata BSIs. Future studies will be needed to evaluate the effect of decreasing fluconazole use on rates of fluconazole-resistant C glabrata BSIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.